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Abstract: 
Virtual high throughput screening (VHTS) was performed to assess possible interactions which might occur between 
commercially available triphenylphosphonium (TPP) cations and estrogen receptor α (ERα) that could be exploited to 
design novel ERα modulators.  One application of TPP cations is for delivering bioactive molecules to targets in 
mitochondria as the large membrane potential of mitochondria leads cations to accumulate inside them.  The estrogen 
receptors (ERs) α and β, normally activated by the endogenous hormone 17β-estradiol, are responsible for controlling 
transcription of nuclear DNA necessary for human development and reproduction. ERs are also associated with the plasma 
membrane and have been found in the mitochondria of a variety of cell types. Selective estrogen receptor modulators 
(SERMs) are synthetic compounds which are used to modulate ER activity.  Different SERMs display varying combinations 
of agonistic, antagonistic and neutral effects upon estrogen receptors depending upon the tissue type and cellular location of 
the receptor.  Thus, they are being employed to treat a range of ER-related disorders.  A common feature shared by many 
SERMs is the close arrangement of three aromatic rings similar to TPP cations.  Given this structural similarity, the 
estrogenic activity of triphenyl phosphonium salts was investigated using the automated docking program eHiTS.   
Compounds were docked into ten different crystal structures of ERα.  Structures were chosen based upon eHiTS ability to 
accurately identify the majority of estrogenically active compounds given a set of active and decoy molecules.  The results of 
the VHTS suggest hybrids of TPP cations and known SERMs could serve as potent mitochondrial SERMs.    
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Background: 
The estrogen receptors (ERs) α and β are intracellular 
proteins responsible for controlling transcription of genes 
necessary for human development and reproduction.  ER 
activity is normally modulated by the endogenous hormone 
17β-estradiol (E2) which binds to nuclear ERs resulting in 
recruitment of coregulatory complexes.  Due to the 
important role the ER signaling networks play in 
developmental, reproductive, skeletal, neural, and 
cardiovascular processes, irregularities in ER activity can 
lead to a number of conditions including breast, ovarian, 
colon, prostate, and endometrial cancers.  Selective 
estrogen receptor modulators (SERMs) such as tamoxifen 
and raloxifene have been successful in the treatment and 
prevention of both breast cancer and osteoporosis [1].  
SERMs are compounds which display agonist, antagonist, 
or neutral effects on ER activity dependent upon the 
specific ER subtype and cell type in which the estrogen 
receptor is present. 
 
In addition to being found in the nucleus as well as in and 
adjacent to the plasma membrane, ERα and ERβ have also 
been located in the mitochondria of a variety of cell types 
[2].  E2 has been known to have an inhibitory effect on 
apoptosis and mitrochondrial ERs are believed to make a 
direct, specific contribution to this.  Nuclear ERs when 
activated bind with Estrogen Response Elements in nuclear 
DNA and sequences similar to these EREs have been 
found in mitochondrial DNA.  Electrophoretic mobility 
shift assays and surface plasmon resonance studies have 
revealed that mitochondrial ERs do in fact bind to these 
sites  [3].  Current evidence also supports mitochondrial 
ERβ serving an anti-apopototic role in rat heart muscle 
subjected to trauma and hemorrhage and activation of 
mitochondrial ERs having a protective effect on cerebral 
blood vessels and cultured endothelial cells.  More 
investigation is required to further elucidate the specific 
mechanisms by which mitochondrial ERs contribute to 
cellular function and dysfunction. 
 
One possible way to elucidate specific roles that 
mitochondrial ERs have in cellular function would be to 
design a small molecule which would be capable of 
selectively affecting mitochondrial ERs.  One method for 
delivering small molecules to the mitochondria is to exploit 
the fact that there is a large membrane potential of 150-180 
mV across the mitochondrial inner membrane, with the 
inside of mitochondria being negatively charged [4].  Due 
to this potential gradient, lipophilic cations, which are able 
to pass through lipid bilayers due to their dispersed charge, 
are able to accumulate 100-500 fold inside the 
mitochondria matrix [5].  This technique has been 
employed to prevent mitochondrial oxidative damage by 
conjugating anti-oxidants to the triphenylphosphonium 
(TPP) cation [6]. 
 
If TPP cations existed which showed estrogenic (or anti-
estrogenic) activity, by exploiting the 100-500 fold 
accumulation of lipophilic cations inside mitochondria, it 
may be possible to rationally design a SERM selective Bioinformation by Biomedical Informatics Publishing Group                             open access 
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towards mitochondrial ERs.  Here, we employ molecular 
docking to consider possible interactions a set of 
commercially available TPP cations could have with ERα.  
A set of 314 compounds available from Sigma-Aldrich 
were screened in silico using the automated docking and 
scoring program eHiTS (electronic High Throughput 
Screening) from SimBioSys Inc. [7, 8].  Compounds were 
docked into ten different X-ray crystallography structures 
of ERα from the Protein Data Bank [9].  A test set of 
known ERα binders and decoy molecules was created in 
order to test eHiTS ability to accurately dock and score 
compounds. Ten X-ray crystallography structures of ERα 
from the Protein Data Bank (PDB) were chosen which 
eHiTS was able to use to identify the majority of active 
compounds from the test set.  After docking and scoring 
the set of TPP cations, the orientations of top scoring 
molecules were examined to consider which molecules 
would be best for further optimization.  While a variety of 
TPP cations with various moieties may possibly bind with 
ERα with the TPP cation part of the compound inside of 
the ligand binding pocket of ERα, results suggest that one 
might be able to produce strong ERα binders which could 
target mitochondria by conjugating known SERMs to the 
TPP cation.  In vitro testing has yet to be conducted to 
verify the estrogenic activity of these compounds.  If some 
of these compounds do show estrogenic activity, further 
work should be done to optimize these structures to 
maximize activity and determine if there is a concentration 
range where a compound might affect principally 
mitochondrial ERα.               
 
Methodology: 
All docking and scoring was performed with the software 
eHiTS (electronic High Throughput Screening) Lightning 
(Version 8.0.rc2.4) by SimBioSys Inc. running on a Sony 
PlayStation 3.  eHiTS docks small molecules into a protein 
structure by first dividing up the small molecules into rigid 
fragments and flexible chains.  The rigid fragments are 
docked independently into the receptor site, generating 
multiple poses which are stored in DockTable, an SQL 
database so that common molecular fragments that occur in 
multiple small molecules can be reused.  A graph matching 
algorithm enumerates all compatible fragment pose 
combinations and then flexible chains are fitted between 
the rigid fragment poses to satisfy steric criteria imposed 
by the fragments and the receptor site.  Finally, local 
minimization is performed using a modified Powell's 
method on the reconstructed structures to obtain the final 
poses.  An empirical scoring function is used several times 
during the algorithm including during evaluation of rigid 
poses, selection of best graph matching solutions, flexible 
chain fitting, and final local optimization. 
 
To handle the problem of protein flexibility, eHiTS 
provides a “soft” representation of the protein structure in 
three respects.  The eHiTS scoring function utilizes the 
temperature factor information provided in the PDB files to 
attempt in its gauging of the interaction as well as 
considering the probability of the atom positions to create a 
derived empirical scoring function.  eHiTS rotates the 
hydroxyl groups of the serine, threonine and tyrosine 
residues of the protein and also the -NH3+ group of lysine.   
Thus, the interaction flexibility of these is considered even 
though eHiTS does not move the heavy atoms of the main 
or side chains during this process.  Furthermore, the steric 
clash, or van der Waals potential, is considered with a 
“soft” quadratic potential as opposed to the harder 6-12 
potential often employed in force fields. The top scoring 
thirty-two orientations for each compound successfully 
docked are saved and the compounds are ranked by the top 
scoring pose calculated for each structure. 
 
Two sets of compounds were assembled using data from 
the Binding Database [10, 11].  One set of compounds 
contained active compounds which were reported as 
having an inhibition constant Ki of less than 10 nM for 
ERα [12, 13, 14, 15, 16].  The other set of compounds was 
a set of decoy molecules which were found to show no 
activity even at concentrations greater than 100000 nM 
[17].  Ten PDB structures were chosen which were able to 
accurately rank the majority of actives from the decoy 
molecules -- 1R5K, 1SJ0, 1XP1, 1XP6, 1XP9, 1XPC, 
1YIM, 1YIN, 2OUZ, and 3ERT.  To validate this, the best 
(i.e. minimum score) a molecule received across any of the 
above structures was taken and a Student’s t-test was 
performed comparing the scores between active and decoy 
molecules.  A p-value of less than 0.0001 suggested that 
there was a significant difference between the scores 
actives received and the scores decoys received with the 
active molecules having better scores.  
 
A library of triphenylphosphonium salts and cations was 
assembled through a substructure search of the Sigma-
Aldrich catalogue.  Anions were removed from the salts 
and redundant compounds were removed to form a library 
of 315 compounds.  3D coordinates for the structures were 
generated using the Molconvert utility from ChemAxon 
[18].  Compounds were docked into the ten X-ray 
structures with standard settings in eHiTS.  PyMol from 
DeLano Scientific was used for visual inspection of results 
and graphical presentations.  After observing an interesting 
orientation of one of the higher scoring phosphonium 
cations, a structure which combined the phosphonium 
cation with the co-crystalized ligand was also tested using 
the same settings. 
 
Discussion: 
eHiTS scoring function is given in units of pKi and thus 
more negatively scoring compounds are theoretically better 
binders.  However, reliably accurate scoring of compounds 
aligned into protein structures using docking programs 
continues to be a problem [19, 20].  In general, a “good” 
performing scoring function should be able to rank ligands 
majoritively over non-ligands given a set of actives and 
decoys for a particular protein structure.  Performance 
among docking programs and scoring functions tends to 
vary depending upon the protein structure.  Reliably 
ranking active ligands in order of binding affinity is rarely 
achievable.  eHiTS features a customizable scoring 
function which can be trained using either “Validation 
Training,” “Enrichment Training,” or both.  Neither of 
these features was utilized however due to technical issues 
which were encountered while using eHiTS Lightning.   
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Instead, a set of active compounds (defined as compounds 
with reported Ki for estrogen receptor α less than 10 nM) 
and decoy compounds (defined as compounds with Ki for 
estrogen receptor α greater than 100000nM) were 
assembled using results on BindingDB.org.  The active set 
included fourteen compounds and the decoy set included 
twenty compounds.  Using eHiTS to dock and score these 
compounds into various PDB structures of estrogen 
receptor  α  structures, ten PDB structures were chosen 
which returned scores which ranked the majority of active 
compounds above decoy molecules without performing 
additional training of eHiTS’ scoring function.  Shown in 
Table 1 are selected results from eight of those structures, 
including the top two scoring and worst scoring active 
compounds along with the top two scoring and worst 
scoring decoy molecules. 
 
Also shown in Table 1 (supplementary material) are all 
TPP cations tested which scored better than -12 on at least 
one of the ERα structures used in this study.  Originally, it 
was hypothesized that eHiTS might orient the TPP cations 
with conjugated moieties in the ERα ligand binding pocket 
such that the TPP cation part of the compound would be 
inside the pocket with the moiety extending outward to the 
surface of the receptor.  In this way, the compound would 
resemble the binding pose of many known SERMs which 
have a clustered ring system inside the pocket with a side 
arm extending outward (see Figure 1a).  However, it was 
found that most of the top scoring poses had the moiety 
inside the pocket, pointing towards or wrapping around the 
side of the pocket (see Figures 1b, 1c, 1d).  While these 
compounds appeared to score well, none were in the range 
of the best performing known SERMs from the active set.  
While this does not eliminate the possibility that some of 
the TPP cations might have ERα modulating abilities, 
altering a high scoring TPP cation to improve its score to 
the range of the higher performing known actives should 
increase the likelihood of producing an active compound. 
 
 
Figure 1: (a) Lasofoxifene as it was found when co-crystalized with ERα (PDB structure 2OUZ).  (b, c, d) Various top-
scoring TPP cations docked into the ligand binding pocket of ERα structure 2OUZ after the co-crystalized ligand has been 
removed.  Note how the moiety bound to the TPP cation is oriented towards the side of the pocket and now facing out of the 
cavity (towards the surface of ERα).  (e) A TPP cation which scored well (eHiTS score = -11.035) with the TPP cation part 
on the surface of the receptor with the bound moiety extending inwards.  It was docked without lasofoixfene being inside the 
pocket, although lasofoxifene is shown with it to show the overlap.  (f) Lasofoxifene/TPP cation hybrid compound as it 
docked into 2OUZ (eHiTS score = -14.119).    Bioinformation by Biomedical Informatics Publishing Group                             open access 
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An opportunity for this path to be explored arose when 
some TPP cations were found to be oriented with the TPP 
cation on the outside of the ligand binding pocket with the 
bound moiety extending inwards (see Figure 1e).  One 
TPP cation was chosen which had this orientation when 
docked into PDB structure 2OUZ and was found to have a 
convenient overlap with the co-crystalized ligand in that 
structure.  The original TPP cation had a score of -11.035 
when docked into 2OUZ.  The co-crystalized ligand of 
2OUZ (lasofoxifene) had a score of -12.483 when 
redocked into the structure with an RMS difference of 
1.364 angstroms off from the original co-crystalized 
structure.  The hybrid structure produced by combining the 
TPP cation seen in Figure 1e with lasofoxifene was found 
to have the significantly better score of -14.119 when 
docked into 2OUZ (see Figure 1f), putting it into the same 
range as the top perform actives.  However, when this 
hybrid molecule was docked into other ERα structures 
evaluated in this study it was not scored as well.  Only in 
PDB structure 1SJ0 did it score in the active range.  In 
1XPC it docked but scored poorly and in the other 
structures eHiTS returned a score of zero.  Further testing 
of TPP/SERM hybrids to produce more realiable 
compounds should be a future direction of study. 
 
Conclusion: 
Due to the importance of proper ER functioning in a 
multitude of bodily processes, compounds which can 
selectively modify ERs can serve as important therapeutic 
tools.  Mitochondrial ERs are known to play roles in 
cellular processes, although their specific pathways are still 
being uncovered.  The design of a lipophilic cationic 
SERM from TPP cations may provide a novel method for 
probing the mechanisms of mitochondrial ERs.  In silico 
screening of commercially available TPP cations using 
eHiTS suggested that TPP cations could bind with ERα, 
although not necessarily in the hypothesized orientation 
with the moiety bound to the TPP cation oriented outward 
towards the surface of the receptor.  However, docking 
results suggested that another strategy for optimizing TPP 
cations to act as estrogen receptor modulators is to use a 
fragment-based approach in order to produce TPP/SERM 
hybrids.  With the SERM part of the compound inside of 
the ERα ligand binding pocket and the TPP cation filling 
the opening to the pocket, this hybrid molecule could 
potentially bind more tightly to ERα than either of the 
individual components could.  Thus, hybrid molecules 
incorporating known SERM motifs could serve as high 
affinity estrogen receptor ligands.  This serves as a future 
direction of study for designing novel SERMs, particularly 
as a lipophilic cationic SERM could function as a 
mitochondrial SERM. 
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Active  1  (9803972)  -14.589 -12.931 -12.958 -14.589 -14.508 -13.462 -13.559 -14.422 -13.391 
Active  2  (9894892)  -13.343 -12.247 -12.755 -13.173 -13.067 -13.257 -12.168 -13.343  -12.84 
Active  4  (4859)  -13.596 -12.369 -12.813 -12.634 -13.596 -12.279  -12.12 -13.029 -12.109 
Active  7    (8461628)  -9.82  -9.26 -9.128  -9.82 -9.366 -9.385 -9.484 -9.722 -9.313 
Decoy  4  (9372960)  -9.243 -8.684 -8.199 -9.102 -9.243  -8.6 -8.641 -8.777 -8.522 
Decoy  7  (9418926)  -9.341 -7.746 -8.681 -8.873 -9.341 -8.465 -7.961 -8.262 -8.313 
Decoy  9  (9328424)  -10.638  -9.518 -10.015 -10.638  -9.458  -9.19  -9.026 -10.183  -9.549 
Decoy  20  (9462726)  -7.024 -6.588 -6.821 -7.024 -6.729 -6.593 -6.391 -6.766 -6.592 
MFCD00796283  -13.083  -13.083 -10.02 -8.962  -10.758 -5.356  -10.694 -7.684 -9.578 
MFCD00795212  -12.774  -9.476 -12.414 -12.557 -11.543 -11.943  -10.81 -11.593 -12.774 
MFCD00191781  -13.416 -9.457 -9.013  -13.416 -9.583 -7.516 -9.646  -12.771 -9.079 
MFCD02684954  -13.012  -9.687 -11.756 -13.012 -12.547 -10.776 -10.993 -11.509 -12.322 
MFCD00965302  -12.955 -10.857 -11.074 -12.955  -10.94 -10.287  -11.82 -11.844 -11.498 
MFCD00051886  -12.915 -10.577  -11.87 -12.915 -12.362  -9.905  -10.54 -12.486 -11.679 
MFCD00043160  -12.902  -9.177  -10.19 -12.783 -12.902 -11.309 -10.206  -11.99  -9.333 
MFCD01096622  -12.772  -10.559  -11.523  -12.772  -8.96 -11.31 -9.385 -9.878 -8.093 
MFCD02684953  -12.781 -10.535 -11.235 -12.742 -12.781 -11.561 -12.246 -12.129 -11.577 
MFCD00031658  -12.695  -9.256 -10.872 -12.695 -10.831  -9.682  -9.283 -12.322 -10.187 
MFCD00159395  -12.675  -9.884 -10.112 -12.675 -11.434  -9.817  -9.661 -11.035 -11.593 
MFCD01325781  -12.521  -9.91  -9.897 -12.521 -10.466 -10.987  -9.863  -11.21 -10.288 
MFCD00031643  -12.702 -11.152 -10.992 -11.621 -12.702 -10.851 -10.588 -11.524 -10.453 
MFCD00228673  -12.662  -9.476 -11.026 -11.752  -9.162 -10.722  -8.669 -12.662  -9.809 
MFCD00226703  -12.523 -11.384  -10.4 -11.818  -9.822 -10.214  -9.743 -12.523 -10.747 
TPP/Lasofoxifene 
Hybrid 
-14.119  -14.119 ----  -13.018 ---- ---- ----  -5.566 ---- 
Included are the top three scoring actives screened, the lowest scoring active screened, the top three scoring decoys screened, 
the lowest scoring decoy screened (all identified by their ChemSpider ID number – www.chemspider.com), all TPP cations 
screened which scored better than -12 on at least one ERα structure (identified by the MDL number for their corresponding 
commercially available salt form), and the TPP/Lasofoxifene hybrid seen in Figure 1f. 